PRMT5 inhibition induces a histone methylation switch that drives chromatin plasticity, drug resistance, and metastatic progression
Colin E Fowler, Natalie A. O’Hearn, Nicole Henning, Anthony J. Griffen, Ziyang Ye, Nicolas Mathey‐Andrews, Griffin Salus, Renin Hazan, Tyler Jacks, Aurora Burds, Helen Mueller, Yadira M. Soto‐Feliciano, Lindsay LaFave, Jacqueline A. Lees
This study shows PRMT5 inhibition causes splicing defects and epigenetic changes leading to drug resistance and metastatic progression in lung adenocarcinoma.
bioRxiv · Oct 10, 2026 · PreprintCancer Biology